Some like it hot!

Journal of Clinical Oncology

Volumn 19, Issue 19, 2001, Pages 3908-3911

  Cheson, B D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHOMA; PRIORITY JOURNAL;

EID: 0035478183     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.19.3908     Document Type: Editorial

References (29)

1. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
2. Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
3. Pivotal study of Iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
4. Follicular lymphoma: Prognostic factors for response and survival
5. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
6. Iodine-131 tositumomab for patients with transformed low-grade non-Hodgkin's lymphoma: Overall clinical trial experience
7. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
8. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory lowgrade and transformed low-grade B-cell non-Hodgkin's lymphomas
9. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multicenter phase II study
10. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma
11. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
12. Rituximab dose-escalation trial in chronic lymphocytic leukemia
13. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
14. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma
15. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
16. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
17. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
18. Synergistic cytotoxicity of iodine-131-anti-CD20 antibodies and chemotherapy for treatment of B-cell lymphomas
19. Rituximab sensitizes non-Hodgkin's lymphoma B cell lines to taxol-mediated cytotoxicity and synergy is achieved in both apoptosis and necrosis
20. Fludarabine synergizes with anti CD20 monoclonal antibody rituximab in complement mediated cell lysis
21. Rituximab inactivates signal transducer and activator of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bc1- 2 and sensitization to cytotoxic drugs
22. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized trial
23. Iodine I 131 tositumomab for previously untreated follicular lymphoma (FL)
24. Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL)
25. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patents with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
26. Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
27. Response to Zevalin is superior to response to rituximab regardless of age and extent of disease
28. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
29. The purine analogs: A therapeutic beauty contest